Terrie Curran - 27 Aug 2026 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Reporting relationship: Director
Issuer ticker: ARQT
Reported as of: 27 Aug 2026
Net transaction value: -$956,123
SEC form: 4
Accepted by SEC: 28 Aug 2026, 17:40:02 UTC
Prior SEC filing: 24 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Latha Vairavan, as Attorney-in-Fact for Terrie Curran

Key filing fact

Terrie Curran filed Form 4 for Arcutis Biotherapeutics, Inc. (ARQT) on 28 Aug 2026.

Key facts

This page summarizes Terrie Curran's Form 4 filing for Arcutis Biotherapeutics, Inc. (ARQT).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 28 Aug 2026, 17:40.

Change

Previous filing in this sequence was filed on 24 Aug 2026.
Current net transaction value: -$956,123.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001690298 Primary reporting owner

Curran Terrie

Relationship: Director
Address: C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE
Signature: /s/ Latha Vairavan, as Attorney-in-Fact for Terrie Curran
Signature date: 28 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ARQT transaction

Common Stock

Options Exercise

Transaction value
Shares: +11,148
Change %: +47%
Price: $7.51^*
Shares after: 34,674
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F1

ARQT transaction

Common Stock

Sale

Transaction value: $279,028
Shares: -11,148
Change %: -32%
Price: $25.03
Shares after: 23,526
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F1, F2

ARQT transaction

Common Stock

Options Exercise

Transaction value
Shares: +27,052
Change %: +115%
Price: $8.63^*
Shares after: 50,578
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F3

ARQT transaction

Common Stock

Sale

Transaction value: $677,095
Shares: -27,052
Change %: -53%
Price: $25.03
Shares after: 23,526
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARQT transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -11,148
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,148
Exercise price: $7.51
Footnotes: F1, F4

ARQT transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -27,052
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 27 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,052
Exercise price: $8.63
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.

Footnote F2

The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F3

The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.

Footnote F4

The option is fully vested.